Overland Park, KS – Ronawk, a leading biotechnology company, proudly announces the launch of STELLα, a state-of-the-art non-clinical contract research organization (CRO) dedicated to driving innovation in the life sciences industry. The addition of STELLα to Ronawk’s portfolio represents a significant milestone in the company’s growth and expansion, further solidifying its position as a strategic contributor to the region’s growing biotech ecosystem.
STELLα, which derives its name from the Latin and Greek words for “star” and “pillar,” respectively, symbolizes the organization’s commitment to illuminating and accelerating the path to scientific breakthroughs. With a focus on
convenience, service, and quality, STELLα strives to provide an unparalleled experience for its clients.
“We are thrilled to introduce STELLα to the market, as it represents a new era of non-clinical research services,” said A.J. Mellott, CEO and Co-Founder of Ronawk. “Our mission has always been to accelerate scientific discovery, and with the launch of STELLα, we can offer a comprehensive suite of services that cater to the unique needs of the region by helping our customers achieve their research goals more efficiently and effectively.”
STELLα’s core services include tissue and cell culture, histology and immunolabeling, bio-characterization, and microscopy. In addition, the CRO offers partnering services such as animal studies and electrophysiology. These services are designed to support a wide range of research projects, from early-stage discovery to preclinical development.
“Our region is already recognized for its outsized cluster of CROs, and Ronawk’s launch of STELLα is an incredible complement to the host of biotech organizations and universities in Kansas City,” said Dennis Ridenour, President and CEO of BioNexus KC. “STELLα will help support and accelerate a variety of cutting-edge research projects, while Ronawk develops innovative technologies and continues to invest in the future of Kansas City.”
By combining Ronawk’s expertise in tissue engineering and regenerative medicine with STELLα’s innovative non-clinical research capabilities, the company aims to revolutionize the biotech landscape by providing cutting-edge solutions to researchers around the world. The launch of STELLα marks a new chapter in Ronawk’s growth and demonstrates its commitment to providing unparalleled value to the market.
For more information about STELLα and its comprehensive suite of non-clinical research services, visit STELLASciences.com or contact Scott Leigh, Chief Revenue Officer at [email protected].
Social: LinkedIn STELLα
Ronawk is a leading biotechnology company specializing in advanced tissue mimetic technology and regenerative medicine. With a focus on innovation and excellence, Ronawk is committed to accelerating scientific discovery and
providing state-of-the-art solutions to researchers in the life sciences industry. The launch of STELLα, its non-clinical contract research organization, marks a significant milestone in the company’s growth and further solidifies its position as a key contributor in the biotech sector.
Tell Us What You Think!